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Abstract
Background: Erythema migrans represents an early cutaneous and most common manifestation of Lyme borreliosis.
Recommendations regarding pharmacological agents, dose and duration of treatment are subject of intense
debate. This review aims to explore differences in efficacy and safety between pharmacological treatments
and control treatment.
Methods: To identify relevant studies, we will conduct a systematic literature search. We will include randomised
controlled trials (RCTs) and non-RCTs. Eligible comparative studies need to (1) consider patients with a diagnosis of
erythema migrans resulting from Lyme borreliosis and (2) compare different pharmacological agents against each
other, against any other non-pharmacological treatment, placebo or no treatment. Two review authors will
independently assess included studies for risk of bias according to the methods of the Cochrane Handbook
for Systematic Reviews of Interventions and related to specific study designs. We will address patient-relevant
outcomes including clinical remission of cutaneous symptoms, any treatment-related adverse events, quality of
life and progressive symptoms such as neuroborreliosis or Lyme carditis and flu-like symptoms. Provided that
the identified trials are comparable in terms of clinical issues, combined estimates will be provided.
Estimations of treatment effects will be calculated based on a random effects model. Heterogeneity will be
evaluated based on I2 and chi-square test. In case of significant heterogeneity, a pooled estimate will not be
provided, but heterogeneity will be investigated on the basis of methodological and clinical study aspects.
We plan subgroup analysis to reveal potential differences in the effect estimates between patient populations
and treatment specifications. We will consider risk of bias using sensitivity analyses to decide whether to rely
on the pooled estimates. The quality of a body of evidence for individual outcomes will be assessed using
the GRADE approach.
Discussion: Benefits and harms of pharmacological treatment in erythema migrans have not yet been adequately
assessed. This systematic review will evaluate and summarise available evidence addressing benefits and harms of
different pharmacological treatments. In addition, this summary of clinical evidence will inform decision-making
between clinicians and patients and will play an important part in patient care.
Systematic review registration: PROSPERO: CRD42016037932
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Background
Lyme borreliosis (Lyme disease) is an infectious disease
caused by spirochetes and transmitted by tick bites.
Borrelia burgdorferi s. l. complex infection is known in
most northern hemisphere countries in Europe, USA
and Asia according to the distribution of the respective
Ixodes ticks [1–6]. Clinical manifestations of Lyme borre-
liosis are split into early localised (such as erythema
migrans (EM, also known as erythema chronicum migrans),
borrelial lymphocytoma), early disseminated (multiple
erythemata migrantia (MEM), early neuroborreliosis, Lyme
carditis) and late manifestations (such as acrodermatitis
chronica atrophicans, late neuroborreliosis, Lyme arthritis).
From the primary skin manifestation, Borrelia burgdorferi
can disseminate to other organs.
The typical clinical sign of early skin infection with B.
burgdorferi is a circular, outwardly expanding red patch
with central clearing called EM. Typically EM occurs at
the site of the tick bite after three to 32 days [7–10]. EM
associated with early infection is found in about 70–90 %
of patients [5, 11, 12] and can have a range of appearances
including the typical bull-s-eye lesion, but atypical lesions
are also common [7–9, 13, 14]. People affected with Lyme
borreliosis can also experience flu-like symptoms, such
as headache, muscle and joint paints, fever and malaise
[15]. The current literature provides no standardised
criteria for the diagnosis of Lyme borreliosis but case
definitions for surveillance by the Centers for Disease
Control and Prevention (CDC) [16] or epidemiological
issues by the European concerted action on Lyme
borreliosis (EUCALB) [10] were provided.
Particularly, untreated early localised infection with
B. burgdorferi can progress to disseminated manifesta-
tions such as neuroborreliosis in 10–20 % of patients
[3, 5]. Other disseminated manifestations of Lyme borre-
liosis include Lyme carditis, present in <1 % of patients
in Europe [3, 17] and <10 % of patients in the USA
[18], Lyme arthritis, present in 2–7 % of patients in
Europe [3] and <10 % in the USA [17] or acrodermatitis
chronica atrophicans, occurring in <5 % of patients in
Europe [3, 17, 18].
Antibiotic treatment represents the first-line therapy in
Lyme borreliosis. Thereby, the most common agents in
use are doxycycline, amoxicillin, cefuroximaxetil, azithro-
mycin and penicillin. While probenecid was used as co-
administration in treatment with amoxicillin to increase
bioavailability in trials conducted in the USA, probenecid
is not used anymore when treating with amoxicillin.
While the duration of treatment of persistent symp-
toms attributed to borreliosis is major area of debate,
there is an overall consensus in favour of antibiotic treat-
ment but dosage and duration of treatment is still subject
of debate. For example, the guidelines of the Infectious
Disease Society of America (IDSA) [18] and the German
Dermatological Society (DDG (Deutsche Dermatologische
Gesellschaft)) [19] recommend doxycycline 100 mg twice
a day for 14 to 21 days, whereas the International Lyme
and Associated Diseases Society (ILADS) recommends a
more extended treatment duration of doxycycline for up
to 42 days [20]. The ILADS also emphasises that antibiotic
treatment regimens of 20 or fewer days should not be
given to patients with EM because failure rates may be
unacceptably high. In contrast to the most common pre-
scribed dose of 200 mg per day, the German Borreliosis
Society (Deutsche Borreliose Gesellschaft (DBG)) recom-
mends a higher dosage of 400 mg [21]. Particularly in
Europe, amoxicillin is also commonly used. Different clin-
ical trials demonstrated that it is effective if given in a dose
of 500 mg three times a day in patients with EM [22, 23].
However, treatment recommendations for amoxicillin also
differ between different guidelines. For example, the
ILADS recommends a total dose of 1500 to 2000 mg a
day for 28 to 42 days, while the DBG recommends a much
higher dose of up to 6000 mg a day for at least 28 days. In
contrast, the guidelines of the DDG and IDSA recom-
mend doses between 500 and 1000 mg three times a day
for only 14 to 21 days. The use of combinations of antibi-
otics is advocated by the guideline of the DBG [21]
whereas it is not recommended by any of the others (such
as the IDSA guideline [18]).
It is obvious that conflicting guidelines often arise
when evidence is weak; different methods for guideline
development are used by the organisations or societies
or when benefits and harms of interventions are valued
differently by guideline developers [24]. In regard to the
above presented controversies, a concise risk-benefit
analysis in form of a rigorous conducted systematic re-
view could greatly influence decision-making by clini-
cians to offer the most effective treatment to this patient
population. Due to the fact that Lyme borreliosis may be
associated with different manifestations (see above) for
which a wide range of pharmacological treatment op-
tions is available, we plan a series of reviews on Lyme
borreliosis. Shortly, a review on neuroborreliosis has
already been published by our group [25, 26]. This
systematic review will, therefore, be the second of a series
of reviews addressing efficacy and safety of pharmaco-
logical treatments of adults in different clinical manifesta-
tions of Lyme borreliosis.
Methods
Objectives
This review aims to explore differences in efficacy and
safety between pharmacological treatments and compared
to control treatment in adults with EM. We conducted
this protocol according to the PRISMA-P guideline [27].
The checklist can be found in the Additional file 1.
Torbahn et al. Systematic Reviews  (2016) 5:73 Page 2 of 7
Types of studies
We will include randomised controlled trials (RCTs) and
non-RCTs. For non-RCTs, we will consider both cohort
and case-control studies. Eligible comparative studies
need to (1) consider patients with a diagnosis of EM and
(2) compare different pharmacological agents against
each other, against any other non-pharmacological treat-
ment, placebo or no treatment. We will also include case
series, but they have to report a minimum of 10 patients
and report safety data (or—in our case—progressive
patient-relevant symptoms related to the disease).
We are interested in data from non-RCTs and case
series, because it is assumed that safety data (e.g. rare
adverse effects or progressive symptoms) from these
study types might show a greater external validity than
data from RCTs [28]. In RCTs, data on adverse effects
might be underestimated, as small sample sizes (<1000)
limit the ability to detect rare but serious events. In
addition, RCTs often include highly selected patients in
which rare adverse effects, which may be associated with
patients’ comorbidities or pharmacovigilance, are rarely
detected. Therefore, in RCTs large sample sizes are
needed to identify differences between the treatment
groups and/or establish causality between an adverse
outcome and the intervention [29]. In contrast, non-RCTs
are often based on large databases and long follow-up
times. Therefore, it is more likely that rare adverse
effects or progressive symptoms related to Lyme borre-
liosis for a wide range of patients might be detected
with these study types [29].
We will not apply any other restrictions.
Types of participants
We will include studies where adults (at least 80 % of
study population ≥18 years of age) with a clinically,
(physician-confirmed) early localised skin infection
(EM) were treated with pharmacological agents (at
least in the intervention group). As there are no ob-
jective standard diagnostic criteria for EM available,
we will rely on the definitions for EM provided in the
clinical studies. Patients diagnosed with late or dis-
seminated manifestations of Lyme borreliosis (such as
disseminated EM or neuroborreliosis) will be excluded
from this review.
Types of interventions
We will evaluate any pharmacological agents (such as an-
tibiotics, steroids, analgesics and phytotherapeutic agents),
applied in any dose and in any treatment interval.
Comparative studies need to compare different
pharmacological agents against each other, against any
other non-pharmacological treatment, placebo or no
treatment.
Types of outcome measures
We will address the following patient-relevant outcomes:
 Remission of cutaneous symptoms (healing rate,
improvement): We acknowledge that eradication
of the bacterium would be the most preferable
outcome in the treatment of EM. However, the
proof of Borrelia eradication by direct detection
(culture, PCR) or by detection of B. burgdorferi-
specific antibodies is challenging and not
sufficiently reliable. Therefore, we consider ‘clinical
improvement of EM’ as the most important
patient-relevant outcome for our research question.
If remission is defined other than healing rate
or improvement of cutaneous symptoms in the
included studies, we will use the change of
symptoms described by the authors of the original
studies.
 Any treatment-related adverse events: We will
distinguish between minor adverse events (such
as diarrhea, nausea or Herxheimer reaction) and
serious adverse events (such as mortality, morbidity
or hospitalisation); we will use the adverse events
definitions described by the authors of the original
studies.
 Patient-reported outcomes: The main patient-reported
outcome of interest is health-related quality of life
(such as reported by validated scales (SF-36 [30])).
Other relevant patient-reported outcomes that
will be considered are fatigue, pain, depression,
cognition and sleep.
 Progressive symptoms after treatment: Treatment
failure may result in different manifestations of
Lyme borreliosis (such as neuroborreliosis, Lyme
carditis, Lyme arthritis, acrodermatitis chronica
atrophicans, and flu-like symptoms [10, 18]); reported
symptoms should be measured by validated scales
(such as via the Neurological Impairment Scale (NSI)
[31]; disability should be measured with the modified
ranking scale [32]). When information is lacking or
no valid method was used, which is assumed to be
the case in the majority of studies, outcomes will be
considered as defined by the authors of the original
publication. Lack of validated measurement of
outcomes will be considered in the risk of bias
assessment and robustness of data evaluated in
sensitivity analyses.
If several time points are reported in a primary study,
data from the last reported time point will be consid-
ered. If data permits, results will be presented for short-
term follow-up (6 weeks following start of treatment)
and for long-term follow-up (more than 6 weeks follow-
ing the start of treatment).
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Search methods for identification of studies
To identify relevant studies we will conduct electronic
searches in Medline (via Ovid, from 1950 to present),
Medline in process and other non-indexed citations (via
Ovid), Medline daily update (via Ovid), Embase (via
Ovid, from 1980 to present) and the Cochrane Central
Register of Controlled Trials. Additionally, we will check
reference lists of included studies and contact experts.
Search for ongoing trials or trials completed but not pub-
lished will be conducted in ClinicalTrials.gov (www.clinical
trials.gov) and the WHO International Clinical Trials
Registry Platform (ICTRP) (http://www.who.int/ictrp/
search/en).
The search strategies for the databases mentioned
are shown in Additional file 2. No language restrictions
will be set.
Data collection and analysis
Selection of studies
Firstly, one reviewer will evaluate the titles and abstracts
to determine whether a study possibly meets the eligibil-
ity criteria. Secondly, full texts of all possibly eligible
studies will be retrieved and evaluated independently by
two reviewers for eligibility. Disagreements will be re-
solved by discussion with a third reviewer. For screening,
records will be imported into the reference managing
software Endnote X7 (Thomson Reuters).
Data extraction and management
Two review authors will independently extract data from
the full texts of included studies using a specifically de-
veloped data extraction form. The data extraction form
will be piloted.
Information will be collected on the following items:
 Study characteristics (first author, geographical
origin of study setting, year of publication, start and
end of study, study design, number of arms, sample
size, duration of follow-up)
 Participant characteristics (age, sex, numbers
of participants, place of residence, establishment
of diagnosis, diagnostic results, case definitions,
disease manifestations, inclusion and exclusion
criteria in the included studies, baseline
imbalances between study arms and possible
confounders (number of patients with
disseminated infections at study entry, delay
between onset of symptoms and treatment,
previous treatment, baseline level of antibodies,
co-medication, co-morbidities and other confounders
as reported by the authors))
 Intervention and comparator details (sample size for
each treatment arm, dose and type of interventions,
route of delivery, dose adjustment based on body
weight, duration of treatment, withdrawals and
drop-outs)
 Outcome measures (description of assessment tools
used, data for continuous/dichotomous/categorical
efficacy variables, unit of measurement, upper and
lower scale limits, collected and reported time
points of measurement).
When adjusted analyses are available in primary stud-
ies, these adjusted estimates of treatment effects will be
used. Otherwise, we will extract the unadjusted data as
reported in the primary study. Data will be entered into
Review Manager (RevMan 5.3) by one of the reviewers
and checked by a second reviewer [33].
Discrepancies in data extraction or entry will be resolved
by discussion with a third reviewer. Reviewers will not be
blinded to study author, journal or institution.
Assessment of risk of bias
The assessment of risk of bias (RoB) will be performed
by two reviewers independently considering the follow-
ing domains according to the Cochrane risk of bias tool
for RCTs: sequence generation, allocation concealment,
blinding (of participants, personnel and outcome asses-
sors), incomplete outcome data, selective outcome
reporting and other sources of bias for the RCTs [34].
According to the Cochrane Handbook, these items will
be described as having ‘low’ , ‘high’ or ‘unclear’ RoB [34].
Bias in comparative studies will be evaluated separately.
The following domains will be addressed for non-RCTs:
bias due to confounding (such as age, time from onset
of symptoms until treatment), bias in selection of partici-
pants into the study, bias in measurement of interven-
tions, bias due to departures from intended interventions,
bias due to missing data, bias in measurement of out-
comes, bias in selection of the reported result and overall
bias. These will be assessed according to the ‘Cochrane
risk of bias tool for non-randomised studies’ (ACROBAT-
NRSI) [35]. According to the ACROBAT-NRSI, these
items will be judged as ‘low’, ‘moderate’, ‘serious’, ‘critical’
or ‘unclear’ risk of bias [35]. At the time of writing this
protocol, this tool is being revised.
We expect that the major confounders which could in-
fluence effect measures in EM are ‘time from onset of
symptoms until treatment’ , ‘co-morbidities’ , ‘intake of
drugs that are not part of treatment’ , ‘geographical ori-
gin’ and ‘age’. ‘Time from onset of symptoms until treat-
ment’ is included in the ACROBAT-NRSI tool in the
domain ‘bias due to confounding’. In the event of
disagreement, consensus will be achieved through a
discussion with a third reviewer. According to the rec-
ommendations for the ACROBAT-NRSI, no studies
assessed as having a ‘critical’ RoB will be included in any
data synthesis.
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Measures of treatment effect
We will analyse outcomes measured with a scale as con-
tinuous outcomes. If more than one scale is used to
measure an outcome in the very same study, only the
measurement on a validated scale will be considered. In
the case when more than one validated or more than
one but only scales that are not validated are reported
for one outcome, we will use the results provided by the
scale which is mostly used in the other included studies.
The treatment effect for each continuous outcome
(such as improvement of EM, patient-reported outcomes
such as quality of life, progressive symptoms such as
headache or complications such as disability) will be
expressed as a mean difference (MD) with 95 % confi-
dence interval (CI). Where continuous outcomes are
measured using different scales, the treatment effect will
be expressed as a standardised mean difference (SMD)
with 95 % CI. As recommended by Guyatt et al., when
possible, the treatment effects will be additionally
expressed by the ratio of means (RoM) with 95 % CI to
facilitate interpretation [36, 37].
The treatment effect for dichotomous outcomes (such
as presence of EM, presence of progressive symptoms or
adverse events) will be expressed as a risk ratio (RR) or
odds ratio (OR) in case of case-control studies with 95 %
confidence intervals.
If data do not permit analysis of ‘cutaneous symptoms’
as a continuous outcome, we will use the reported data
from primary studies and treat this outcome as a dichot-
omous outcome ‘presence of cutaneous symptoms’.
Measures of treatment effects will be pooled for RCTs
and non-RCTs, separately.
Unit of analysis
Each patient recruited in included studies will be the
unit of analysis.
Dealing with missing data
Data will be analysed—if possible—on intention-to-treat
(ITT) basis or after recently developed approaches ad-
dressing missing data in clinical trials following the rec-
ommendations for systematic reviewers by Guyatt et al.
[38–40]. We will also check trial registers or contact study
authors trying to get information of missing data. If results
are only reported in graphs, we will estimate the values.
Assessment of heterogeneity
Provided that the identified trials are comparable in
terms of clinical issues (such as no major imbalances or
differences in the included population or the interven-
tions), combined estimates will be provided (depending
on the study design). Thereby, estimations of treatment
effects will be calculated based on a random effects
model [41] and heterogeneity will be evaluated based on
I2 and the statistical test chi square. In case there is sig-
nificant heterogeneity (chi-square p value <0.10 or an
I2 ≥ 75 %), a pooled estimate will not be provided [42].
But heterogeneity will be investigated on the basis of
methodological (such as RoB) and clinical (such as risk
profile of the study population before treatment, pro-
gressive symptoms after treatment in different control
groups) characteristics.
We plan subgroup analysis to reveal potential differ-
ences in the effect estimates between patient populations
and treatment specifications (such as dose, length of
treatment). In addition, we will consider RoB using sen-
sitivity analyses to decide whether to rely on the pooled
estimates. The quality of a body of evidence for individual
outcomes will be assessed using the GRADE approach.
Assessment of reporting biases
We plan to minimise the impact of reporting bias in our
systematic review by ensuring a comprehensive search
for eligible studies including trial registries. A funnel plot
and appropriate statistical tests for small study effects
will be performed if ≥10 studies are available [43].
Data synthesis
Data from RCTs and non-RCTs will be analysed—due to
different evidence levels—separately [44]. Combined es-
timates (based on a random effects model [see above])
will not be provided for studies with considerable imbal-
ances or differences in the included population or differ-
ences in interventions. Pooling of data of non-RCTs will
only be considered among studies with similar design
(such as prospective cohort studies will only be combined
with other prospective cohort studies) and comparable pa-
tients and intervention characteristics. We will calculate
pooled RRs and 95 % CIs using Review Manager (RevMan
5.3) [33]. When significant heterogeneity is found between
comparable studies (chi-square p value <0.10 or I2 > 75 %,
see above), pooled estimates will not be provided. Instead,
a descriptive synthesis of findings will be performed.
Subgroup analysis and investigation of heterogeneity
We plan subgroup analyses to evaluate whether effect
estimates differ between studies with different lengths of
antibiotic treatment (regardless of antibiotic group) within
pre-specified durations (<14 days, 14–21, >21 days). Due
to the clinical importance of antibiotic treatment options,
subgroup analyses focusing on different antibiotics are
also of considerable interest. Therefore, we will evaluate
pre-specified classes of antibiotics (such as doxycycline,
amoxicillin, amoxicillin plus probenecid and cephalospo-
rins, other antibiotics and combinations of antibiotics) in
subgroup analyses. Cephalosporins and penicillins will be
lumped together as beta-lactam antibiotics to be com-
pared to other groups of antibiotics. Also, the adequate
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dose of antibiotic agents is of particular relevance. For ex-
ample, we plan subgroup analyses for daily doxycycline
doses ≤200 mg with doses >200 mg. A subgroup analysis
will be performed to investigate whether treatment effects
differ in relation to case definitions in the primary studies.
The variety of causative organisms in Europe compared to
the USA could also lead to heterogeneity; consequently,
the effect of geographical origin of the study population
and different causative organisms will be evaluated in a
subgroup analysis.
Sensitivity analysis
Sensitivity analyses will be conducted to determine the
impact of bias by exclusion of studies with high risk of
bias. We will particularly value masking of investigators
and the use of a standard classification system for out-
come measures. We will also conduct sensitivity analyses
excluding studies in which causes of missing data are not
reported or if there is an imbalance between study arms
regarding exclusions related to safety aspects or assumed
treatment failures. Pooled effect estimates of studies which
adjusted for confounders (low risk of bias) will be com-
pared with pooled effect estimates of all studies (studies
which adjusted and studies which did not adjust for con-
founders). If there are differences between these estimates,
they will be considered in the results and discussion.
Assessing the quality of evidence
We will use the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) approach
to assess the quality of evidence for each outcome [45].
We will judge the quality of evidence based on the
suggested five criteria for down-rating our confidence in
effects estimates (risk of bias, inconsistency, imprecision,
indirectness, and publication bias) and the three criteria
for up-rating our confidence (large effect, dose–response
gradient and opposing confounding). Based on these
criteria, the quality of evidence judgement can range
from very low to high.
Discussion
Controversy exists about the choice of drug, dose and
length of treatment in the therapy of EM.
Evidence from RCTs on this topic are likely scarce;
therefore, we will perform a comprehensive and system-
atic review of the evidence incorporating RCTs and non-
RCTs examining pharmacological treatments for adults
with EM. In this protocol, possible subgroup analyses
and sensitivity analyses are predefined. Clinically import-
ant and much debated questions regarding differences in
efficacy and safety of varying antibiotics and length of
antibiotic treatment will be investigated. Adverse events
of treatments will be evaluated, for which non-RCTs are
particularly valuable.
In contrast to previous conducted reviews and guide-
lines including patients with EM, our systematic review
will both assess RoB for all included study designs and
appraise the quality of evidence for each outcome accord-
ing to the GRADE approach [18, 46–48]. Our results will
be important to clarify controversies and reduce uncer-
tainty both for patients and healthcare providers. Particu-
larly due to the inclusion of non-RCTs, which often show
longer follow-ups than controlled trials, we expect good
generalisability of the results of this systematic review in
terms of progressive symptoms of EM and patient safety
between the different treatment options. The summary
and evaluation of the available body of evidence may lead
to evidence-based treatment recommendations for EM.
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